Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Meyerhardt JA, et al. Among authors: schrag d. PLoS One. 2012;7(6):e38231. doi: 10.1371/journal.pone.0038231. Epub 2012 Jun 12. PLoS One. 2012. PMID: 22701615 Free PMC article. Clinical Trial.
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB 3rd, Fuchs CS. Meyerhardt JA, et al. Among authors: schrag d. J Clin Oncol. 2004 Jan 1;22(1):166-74. doi: 10.1200/JCO.2004.04.172. J Clin Oncol. 2004. PMID: 14701779
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. Among authors: schrag d. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699
Cetuximab therapy and symptomatic hypomagnesemia.
Schrag D, Chung KY, Flombaum C, Saltz L. Schrag D, et al. J Natl Cancer Inst. 2005 Aug 17;97(16):1221-4. doi: 10.1093/jnci/dji242. J Natl Cancer Inst. 2005. PMID: 16106027 Review.
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.
Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. Chan JA, et al. Among authors: schrag d. Ann Oncol. 2011 Jun;22(6):1367-1373. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7. Ann Oncol. 2011. PMID: 21217058 Free PMC article. Clinical Trial.
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Zhu AX, et al. Among authors: schrag d. Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27. Cancer. 2011. PMID: 21538343 Free PMC article. Clinical Trial.
442 results